Cardiovascular capabilities available on Toshiba's ultracompact high-field MR system were highlighted at the annual meeting of the American College of Cardiology, March 7 to 10 in New Orleans. Vantage, which was formally released at the 2003 RSNA
Cardiovascular capabilities available on Toshiba's ultracompact high-field MR system were highlighted at the annual meeting of the American College of Cardiology, March 7 to 10 in New Orleans. Vantage, which was formally released at the 2003 RSNA meeting, supports a range of CV studies from stroke evaluation to peripheral vascular imaging. The ultrashort bore provides a feeling of openness; Pianissimo technology reduces scan noise. SuperFASE supports morphology studies of vascular structures, including the heart chambers and large vessels, as well as MR angiograms of venous and arterial vessels. Toshiba's parallel imaging technology, called Speeder, allows high-speed, high-resolution imaging, cutting exam time by as much as a factor of three.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.